Clinical Trials on FMR1-related Primary Ovarian Insufficiency

Total 15585 results

Northwell Health

Withdrawn

In Vitro Maturation (IVM) of Human Oocytes (IVM)

Polycystic Ovarian Syndrome (PCOS) | Patients Sensitive to Exogenous Gonadotropins | Ovarian Hyper Stimulation Syndrome (OHSS)

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Breast Carcinoma | Fallopian Tube Carcinoma | Ovarian Neoplasm | Primary Peritoneal Carcinoma

United States
South Plains Oncology Consortium

Terminated

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Ovarian Cancer | Cancer of the Ovary | Primary Peritoneal Carcinoma | Ovary Neoplasms | Cancer of Ovary

United States
NYU Langone Health
Genentech, Inc.

Completed

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Women and Infants Hospital of Rhode Island
Amgen

Terminated

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Medical Research Council
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Spain, Belgium, France, Netherlands, Austria, United Kingdom, Italy, South Africa, Portugal, Ireland
AstraZeneca

Completed

ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Jin Li

Not yet recruiting

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
Khyber Medical University Peshawar

Completed

Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome

PCOS

Pakistan
Ferring Pharmaceuticals

Completed

Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old. (SHOview)

Ovarian Hyperstimulation Syndrome (OHSS)

France
Cairo University

Completed

Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. (FSH)

Infertility

Egypt
Royan Institute

Completed

Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome

Ovarian Hyperstimulation Syndrome

Iran, Islamic Republic of
Podobnik Maternity and Gynecology Hospital

Unknown

Follicular Activation by Fragmentation of Ovarian Tissue (FAFOT)

Diminished Ovarian Reserve

Croatia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
AbbVie

Withdrawn

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Cancer - Ovarian
NanOlogy, LLC
US Biotest, Inc.

Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
Washington University School of Medicine
Sanofi

Terminated

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Ovarian Cancer

United States
University of Lausanne Hospitals
University Hospital, Zürich; Cantonal Hospital of St. Gallen

Completed

[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging

Metastatic Ovarian Cancer | Metastatic Cancer Lung

Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Ovarian Cancer | Peritoneal Cavity Cancer

United States
M.D. Anderson Cancer Center

Recruiting

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
Qi Zhou

Not yet recruiting

A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH ) (PORCH)

1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer

China
Centre Francois Baclesse
Groupement Interrégional de Recherche Clinique et d'Innovation

Completed

Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis (CARPEMAN)

Ovarian Cancer With Peritoneal Carcinosis

France
Taipei Veterans General Hospital, Taiwan
National YangMing University

Completed

Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve

Dehydroepiandrosterone | DHEAS | Gene Expression of Cumulus Cells. | Ovarian Hyper-stimulation Protocol. | Artificial Reproduction Technology.

Taiwan
Bioroma

Unknown

Long Acting GnRH Antagonist in PCOS Women Undergoing IVF

Ovarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome | Invitro Fertilization

Italy
University Hospital, Tours

Unknown

Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses

Ovarian Tumor

France
Zagazig University

Completed

Insulin Sensitizers Role in Control of PCOS Vicious Cycle.

PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Egypt
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Translational Research Center for Medical Innovation...
Japanese Gynecologic Oncology Group (JGOG); Department of Obstetrics and Gynecology... and other collaborators

Completed

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (HITOMI)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Japan
Masonic Cancer Center, University of Minnesota
Incyte Corporation

Completed

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
University of Pennsylvania
Northwest Biotherapeutics

Withdrawn

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cancer

United States
M.D. Anderson Cancer Center
AstraZeneca; Aravive Biologics Inc

Active, not recruiting

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
University of Saskatchewan

Not yet recruiting

Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer

Anaemia in Ovarian Carcinoma

Canada
GeneScience Pharmaceuticals Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Unknown

Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET

Ovarian Hyperstimulation Syndrome

China
Cairo University

Completed

PCOS and US Cavitation

PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Egypt
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Qilu Hospital of Shandong University; Yunnan Cancer Hospital

Not yet recruiting

Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy

Epithelial Ovarian Cancer | Acute Kidney Injury Due to Circulatory Failure
Hospices Civils de Lyon

Recruiting

NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)

Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer

France
University Health Network, Toronto

Completed

18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

Canada
SOTIO a.s.

Completed

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

Ovarian Neoplasms | Ovarian Epithelial Cancer

Czechia, Poland
Yonsei University
National Cancer Center, Korea; Samsung Medical Center; AstraZeneca; Seoul National... and other collaborators

Unknown

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) (KGOG3046)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

Korea, Republic of
Daiichi Sankyo, Inc.

Completed

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

United States
University Health Network, Toronto

Completed

A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

Platinum-resistant Epithelial Ovarian Cancer

Canada
Xian-Janssen Pharmaceutical Ltd.

Terminated

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Epithelial Ovarian Cancer

China
ARCAGY/ GINECO GROUP
AstraZeneca

Completed

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients (RETROLA)

Relapsed Ovarian Cancers Patients

France
CHA University

Recruiting

Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOS

No Condition

Korea, Republic of
Assiut University

Unknown

The Efficacy of Progestins in Treatment of Functional Ovarian Cyst

Functional Ovarian Cyst | Progesterone
National Cancer Institute (NCI)

Active, not recruiting

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

Ovarian Carcinoma | Ovarian Germ Cell Tumor

United States

Clinical Trials on FMR1-related Primary Ovarian Insufficiency

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations